Cargando…

Effectiveness of ChAdOx1 nCoV-19 vaccine during the delta (B.1.617.2) variant surge in India

Detalles Bibliográficos
Autores principales:	Chakrabarti, Sasanka, Chakrabarti, Sankha Shubhra, Chandan, Gourav, Kaur, Upinder, Agrawal, Bimal Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942524/ https://www.ncbi.nlm.nih.gov/pubmed/35338863 http://dx.doi.org/10.1016/S1473-3099(22)00132-3

Ejemplares similares

Rapidly Progressive Dementia with Asymmetric Rigidity Following ChAdOx1 nCoV-19 Vaccination
por: Chakrabarti, Sankha Shubhra, et al.
Publicado: (2022)

Effectiveness of ChAdOx1 nCoV-19 vaccine during the delta (B.1.617.2) variant surge in India – Authors' reply
por: Thiruvengadam, Ramachandran, et al.
Publicado: (2022)

Determinants of COVID-19 Breakthrough Infections and Severity in ChAdOx1 nCoV-19–Vaccinated Priority Groups
por: Kaur, Upinder, et al.
Publicado: (2022)

Long-Term Safety Analysis of the ChAdOx1-nCoV-19 Corona Virus Vaccine: Results from a Prospective Observational Study in Priority Vaccinated Groups in North India
por: Kaur, Upinder, et al.
Publicado: (2023)

A prospective observational safety study on ChAdOx1 nCoV-19 corona virus vaccine (recombinant) use in healthcare workers- first results from India
por: Kaur, Upinder, et al.
Publicado: (2021)

Oxidative Stress, Neuroinflammation, and NADPH Oxidase: Implications in the Pathogenesis and Treatment of Alzheimer's Disease
por: Ganguly, Upasana, et al.
Publicado: (2021)

The Pathogenetic Dilemma of Post-COVID-19 Mucormycosis in India
por: Chakrabarti, Sankha Shubhra, et al.
Publicado: (2022)

Alpha-synuclein, Proteotoxicity and Parkinson's Disease: Search for Neuroprotective Therapy
por: Ganguly, Upasana, et al.
Publicado: (2018)

Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses
por: Thiruvengadam, Ramachandran, et al.
Publicado: (2022)

ChAdOx1 nCoV-19 effectiveness during an unprecedented surge in SARS COV-2 infections
por: Satwik, Ruma, et al.
Publicado: (2021)

High failure rate of ChAdOx1-nCoV19 immunization against asymptomatic infection in healthcare workers during a Delta variant surge
por: Ujjainiya, Rajat, et al.
Publicado: (2022)

Increasing severity of COVID-19 in pregnancy with Delta (B.1.617.2) variant surge
por: Adhikari, Emily H., et al.
Publicado: (2022)

Postvaccinal Encephalitis after ChAdOx1 nCov‐19
por: Zuhorn, Frédéric, et al.
Publicado: (2021)

Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2
por: Pattni, Karan, et al.
Publicado: (2022)

Clinical outcomes in individuals hospitalized with SARS-CoV-2 Delta variant (B.1.617.2) who had been vaccinated with Covishield (ChAdOx1) and Covaxin (BBV-152)
por: Munigela, Apoorva, et al.
Publicado: (2022)

Depression following ChAdOx1-S/nCoV-19 vaccine
por: Uvais, N.A.
Publicado: (2022)

Thromboses of major arteries and ChAdOx1 nCov-19 vaccination
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
por: Greinacher, Andreas, et al.
Publicado: (2021)

Of Cross-immunity, Herd Immunity and Country-specific Plans: Experiences from COVID-19 in India
por: Chakrabarti, Sankha Shubhra, et al.
Publicado: (2020)

Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2
por: Kaur, Upinder, et al.
Publicado: (2020)

Polyarthralgia and Myalgia Syndrome after ChAdOx1 nCOV-19 Vaccination
por: Hyun, Hakjun, et al.
Publicado: (2021)

Portal vein thrombosis associated with ChAdOx1 nCov-19 vaccination
por: Öcal, Osman, et al.
Publicado: (2021)

Reversible radiculomyelitis after ChAdOx1 nCoV-19 vaccination
por: Spataro, Rossella, et al.
Publicado: (2022)

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
por: Schultz, Nina H., et al.
Publicado: (2021)

Widespread Arterial Thrombosis after ChAdOx1 nCov-19 Vaccination
por: Berlot, Giorgio, et al.
Publicado: (2022)

Venous sinus thrombosis following vaccination with ChAdOx1 nCov-19()
por: Morales Varas, G., et al.
Publicado: (2022)

LGI-1 encephalopathy following ChAdOx1 nCov-19 vaccination
por: Garibashvili, Tamara, et al.
Publicado: (2022)

Process- and product-related impurities in the ChAdOx1 nCov-19 vaccine
por: Krutzke, Lea, et al.
Publicado: (2022)

ChAdOx1 nCoV-19 vaccine for SARS-CoV-2
por: Lodge, Archie
Publicado: (2020)

ChAdOx1 nCoV-19 vaccine for SARS-CoV-2
por: Chauhan, Anil, et al.
Publicado: (2020)

Longer intervals and extra doses of ChAdOx1 nCoV-19 vaccine
por: Rogawski McQuade, Elizabeth T, et al.
Publicado: (2021)

Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination
por: Normark, Johan, et al.
Publicado: (2021)

Takotsubo (stress) cardiomyopathy after ChAdOx1 nCoV-19 vaccination
por: Crane, Phillip, et al.
Publicado: (2021)

Thrombotic thrombocytopenic purpura after ChAdOx1 nCoV-19 vaccine
por: Lee, Hui Ping, et al.
Publicado: (2021)

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
por: Ogbe, Ane, et al.
Publicado: (2022)

Post ChAdOx1 nCoV-19 vaccination frontal lobe syndrome
por: Tapdia, Madhusudan, et al.
Publicado: (2022)

DIC-Like Syndrome Following Administration of ChAdOx1 nCov-19 Vaccination
por: Casucci, Gerardo, et al.
Publicado: (2021)

Cerebral venous sinus thrombosis secondary to ChAdOx-1 nCov-19 vaccine
por: Atta, Syed Noman, et al.
Publicado: (2021)

Autonomic dysfunction post-inoculation with ChAdOx1 nCoV-19 vaccine
por: Karimi Galougahi, Keyvan
Publicado: (2021)

Transient cryoglobulinaemic vasculitis following ChAdOx1 nCoV-19 vaccine
por: Ahmer, Sadaf, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_27phnnqaurssj64uholr1p9o9f